News 2024-05-16
Porton at CPhI North America again
We've had an exciting few days at CPhI North America. We want to express our sincere gratitude to all the present and potential future partners we've engaged with. Whether you require assistance with API route scouting, chemistry optimization, or the manufacturing of intermediates, RSM, or finished API, our teams are ready to support you from our locations in Cranbury (NJ), Slovenia, or our sites in China.
If you are focused on drug product development, the Porton team is equipped to aid in the development of tablets, capsules, liquids, or sterile products, starting from pre-formulation and DS-DP coprocessing through to GMP manufacturing, including high-potent product capabilities. Additionally, our global reach extends to the development of topical and transdermal patch products. How can Porton help you? Contact us.
|
Small Molecules CDMO |
TIDES CDMO |
Biologics (Antibody & ADCs) CDMO |
|
|
|
Others
More
News 2025-03-21
Porton's Near-Term Target Validated by the SBTi
March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.
News 2025-03-19
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T Cell Therapy Development
Cranbury, New Jersey, March 19, 2025 — Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies.
